Wedbush analyst David Nierengarten raised the firm’s price target on Artiva Biotherapeutics (ARTV) to $40 from $23 and keeps an Outperform rating on the shares. First results for AlloNK plus rituximab in refractory rheumatoid arthritis met a “best case” upside scenario, with six-month efficacy surpassing a target threshold of 50% of patients achieving ACR50 response, no loss of response in any treatment subjects, and a safety profile supporting outpatient administration, the firm notes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTV:
- Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial
- Artiva Biotherapeutics Announces $300 Million Equity Offering
- Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright
- Artiva Highlights AlloNK RA Data and Phase 3 Alignment
- Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)